A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2009
11/26/2009	WO2009023601A3 Apparatus and methods for treating epilepsy using convection-enhanced delivery
11/26/2009	WO2009004038A3 Pirenzepine and derivatives thereof as anti-amyloid agents
11/26/2009	US20090292026 Treatment of CNS Disorders With trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine
11/26/2009	US20090292025 Novel crystalline forms of armodafinil and preparation thereof
11/26/2009	US20090292021 Anticonvulsive pharmaceutical compositions
11/26/2009	US20090292005 L- alpha -dioleoyl phosphatidyl{14-N-(1-deoxylactito-1-yl)amino-3,6,9,12-tetraoxa}tetra decanol; 2-O-{2-N-(1-deoxylactito-1-yl)aminoethyl} carbamoyl-1,3-O-dioleoyl glycerol; galactose, a suitable spacer and a certain lipid, a drug carrier; efficiently transferred into the liver
11/26/2009	US20090292000 Pyrrolidine derivatives as prostaglandin modulators
11/26/2009	US20090291999 Agent Exhibiting a Neurotropic, Neuromodulator, Cerebrovascular and Anti-Stroke Activity
11/26/2009	US20090291988 Reversible Inhibitors of Monoamine Oxidase A and B
11/26/2009	US20090291983 3-Oxoisoindoline-1-Carboxamide Derivatives as Analgesic Agents
11/26/2009	US20090291982 New Substituted Oxindole Derivative 352
11/26/2009	US20090291978 Enzyme Inhibitors
11/26/2009	US20090291976 Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
11/26/2009	US20090291970 Substituted Aminoethers for the Treatment of Alzheimer's Disease
11/26/2009	US20090291966 Method Of Treating Anxious Major Depressive Disorder
11/26/2009	US20090291963 Substituted indoles
11/26/2009	US20090291954 Medical Use of Triazine Derivatives
11/26/2009	US20090291953 Pharmaceutical salts of reboxetine
11/26/2009	US20090291943 Process for preparing diaminophenothiazinium compounds
11/26/2009	US20090291939 Treating Alcohol And Or Substance Abuse By Antagonizing Alpha 2 Adrenergic Receptors With Weak Dopamine Blocking
11/26/2009	US20090291933 Solid state forms of a pharmaceutical
11/26/2009	US20090291917 Boron-Containing Small Molecules as Anti-Inflammatory Agents
11/26/2009	US20090291909 Aminosugar, glycosaminoglycan, and s-adenosylmethionine composition for the treatment and repair of connective tissue
11/26/2009	US20090291900 Methods for treatment of headaches by administration of oxytocin
11/26/2009	US20090291893 Compositions for the prevention and treatment of neuroinjury and methods of use thereof
11/26/2009	US20090291429 Substances causing differentiation
11/26/2009	US20090291152 Dibenzothiazepine derivatives
11/26/2009	US20090291150 Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
11/26/2009	US20090291134 Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
11/26/2009	US20090291127 Transdermal anti-dementia active agent formulations and methods for using the same
11/26/2009	US20090291123 Opioid Combination Wafer
11/26/2009	US20090291108 Fabric with health care component
11/26/2009	US20090291065 Collection and selection methods of an embryonic-like stem cell population from human adult periodontal follicular tissues
11/26/2009	US20090291050 Particulate materials
11/26/2009	CA2761971A1 Rice bran extracts for inflammation and methods of use thereof
11/26/2009	CA2725534A1 Inhibition of emmprin to treat multiple sclerosis
11/26/2009	CA2725143A1 Methods for treating progressive cognitive disorders related to neurofibrillary tangles
11/26/2009	CA2725045A1 Silent desensitizers of neuronal nachr and methods of use thereof
11/26/2009	CA2725001A1 Dihydroindolone derivatives
11/26/2009	CA2724955A1 Method of treating anxious major depressive disorder
11/26/2009	CA2724842A1 Imidazo[1,2-a]pyridine compounds
11/26/2009	CA2724841A1 Treatment of mitochondrial diseases with an erythropoietin mimetic
11/26/2009	CA2724594A1 Niacin and nsaid combination therapy
11/26/2009	CA2724592A1 Agent for maintenance of induced remission
11/26/2009	CA2724357A1 Novel thiophenediamine derivative having urea structure
11/25/2009	EP2123751A1 Novel peptide
11/25/2009	EP2123672A1 Modulation of IL-2- and IL-15- mediated T cell responses
11/25/2009	EP2123671A1 Immunogenic peptide composition for the prevention and treatment of Alzheimer's Disease
11/25/2009	EP2123669A1 Copolymers for suppression of autoimmune diseases, and methods of use
11/25/2009	EP2123665A2 Inhibitors of interleukin-1Beta converting enzyme
11/25/2009	EP2123655A1 Bis(tetrahydrofuran) compound, method for production of the compound, and use of the compound
11/25/2009	EP2123652A1 Heterocyclic compound
11/25/2009	EP2123643A1 Novel prophylactic and/or therapeutic agent for diabetic neuropathy
11/25/2009	EP2123642A1 Novel prophylactic and/or therapeutic agent for neurogenic pain
11/25/2009	EP2123637A1 Novel curcumin derivative
11/25/2009	EP2123630A1 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative
11/25/2009	EP2123628A1 A process for preparing optical pure milnacipran and its pharmaceutically accepted salts
11/25/2009	EP2123328A1 Galanthamine derivatives, methods for their obtaining and use
11/25/2009	EP2123318A1 Dose dispensing system and apparatus
11/25/2009	EP2123303A1 Ameliorating agent for insulin resistance
11/25/2009	EP2123281A1 Composition for prevention or treatment of disease associated with amyloidosis through inhibition of aggregation amyloid protein and through promotion of degradation of amyloid protein
11/25/2009	EP2123275A1 Process for production of buprenorphine pharmaceutical preparation to be applied to mouth mucosa
11/25/2009	EP2123274A1 Medicinal composition for transdermal absorption, medicinal composition storing unit and transdermal absorption preparation using the same
11/25/2009	EP2123272A1 Adam inhibitor
11/25/2009	EP2123268A1 Pharmaceutical composition for prevention or treatment of disease associated with tear reduction
11/25/2009	EP2123263A1 Composition and method for suppressing lipid peroxidation in erythrocytes
11/25/2009	EP2123262A1 Polyelectrolyte-encapsulated gold nanoparticles capable of crossing blood-brain barrier
11/25/2009	EP2121754A1 Pegylated a fab
11/25/2009	EP2121705A2 A2a adenosine receptor antagonists
11/25/2009	EP2121658A2 Piperazinyl-propyl-pyrazole derivatives as dopamine d4 receptor antagonists, and pharmaceutical compositions containing the same
11/25/2009	EP2121655A1 Novel 2-heteroaryl substituted indoles 695
11/25/2009	EP2121630A1 Fast dissociating dopamine 2 receptor antagonists
11/25/2009	EP2121625A1 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
11/25/2009	EP2121624A1 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
11/25/2009	EP2121623A1 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
11/25/2009	EP2121622A1 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
11/25/2009	EP2121606A1 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
11/25/2009	EP2121602A1 4-(heterocyclyl)alkyl-n-(arylsulfonyl) indole compounds and their use as 5-ht6 ligands
11/25/2009	EP2121582A1 Process for preparing entacapone substantially free of z-isomer, synthesis intermediates thereof and a new crystalline form
11/25/2009	EP2121001A2 Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury
11/25/2009	EP2120997A2 Modulation of activity of proneurotrophins
11/25/2009	EP2120985A2 Compositions and methods for treating psychiatric diseases and disorders
11/25/2009	EP2120957A1 Compounds and uses thereof
11/25/2009	EP2120954A1 Adenosine derivatives as partial and full agonists of a1 adenosine receptors
11/25/2009	EP2120949A1 Use of flibanserin for the treatment of insomnia
11/25/2009	EP2120943A2 Nitroxide radical as a treatment for neurodegeneration
11/25/2009	EP2120937A1 A composition comprising (r)-spiro[l- azabicyclo[2.2.2]octane-3,2'(3'h) -furo[2,3 -b]pyridine (azd0328) and its use in the treatment of alzheimer's disease, adhd or cognitive dysfunction
11/25/2009	EP2120920A2 Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
11/25/2009	EP2120907A1 Psychotropic compounds, compositions and methods of use
11/25/2009	EP2120875A1 Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
11/25/2009	EP2120575A1 Sphingosine-1 -phosphate receptor agonist and antagonist compounds
11/25/2009	EP2120563A1 Compounds and uses thereof
11/25/2009	EP2120557A2 Polyhydroquinoline compounds and dihydropyridine compounds for inhibiting beta-amyloid production
11/25/2009	EP1663398B1 Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors
11/25/2009	EP1558595B1 Piperazinyl and diazapanyl benzamides and benzthioamides
11/25/2009	EP1537135B1 Adenosine a3 receptor agonists
11/25/2009	EP1322299B1 Composition for the transdermal delivery of fentanyl
11/25/2009	EP1242385B1 Cytokine, especially tnf-alpha, inhibitors
11/25/2009	EP1144405B1 Triazole compounds with dopamine-d3-receptor affinity
11/25/2009	EP1113797B1 Use of duloxetine for the treatment of fibromyalgia

1 ... 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 ... 1833